{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:28:41Z","timestamp":1789522121571,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW 107-TDU-B-211-114009 and 111-TDU-B-221-114001"],"award-info":[{"award-number":["MOHW 107-TDU-B-211-114009 and 111-TDU-B-221-114001"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01287-9","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T22:56:16Z","timestamp":1747695376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6337-1448","authenticated-orcid":false,"given":"Sao-Chih","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5052-9445","authenticated-orcid":false,"given":"Chi-Yuan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier Cheng-Hong","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Yen","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Hsuan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7160-2285","authenticated-orcid":false,"given":"Chien-Chin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6090-9000","authenticated-orcid":false,"given":"Yuan-Yeh","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Ling","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Hsuan","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Sin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chih","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-1093","authenticated-orcid":false,"given":"Liang-In","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Kai","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7965-7579","authenticated-orcid":false,"given":"Bor-Sheng","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4021-3281","authenticated-orcid":false,"given":"Jih-Luh","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4513-2472","authenticated-orcid":false,"given":"Feng-Ming","family":"Tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2967-698X","authenticated-orcid":false,"given":"Wen-Chien","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-An","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1384-5593","authenticated-orcid":false,"given":"Hwei-Fang","family":"Tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"1287_CR1","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","volume":"363","author":"TJ Ley","year":"2010","unstructured":"Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A Mutations in Acute Myeloid Leukemia. N Engl J Med. 2010;363:2424\u201333.","journal-title":"N Engl J Med"},{"key":"1287_CR2","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1182\/blood-2011-07-369934","volume":"119","author":"HA Hou","year":"2012","unstructured":"Hou HA, Kuo YY, Liu CY, Chou WC, Lee MC, Chen CY, et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood. 2012;119:559\u201368.","journal-title":"Blood"},{"key":"1287_CR3","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1182\/blood-2012-10-461624","volume":"121","author":"VI Gaidzik","year":"2013","unstructured":"Gaidzik VI, Schlenk RF, Paschka P, St\u00f6lzle A, Sp\u00e4th D, Kuendgen A, et al. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood. 2013;121:4769\u201377.","journal-title":"Blood"},{"key":"1287_CR4","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"1287_CR5","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1200\/JCO.2011.35.4894","volume":"29","author":"F Thol","year":"2011","unstructured":"Thol F, Damm F, L\u00fcdeking A, Winschel C, Wagner K, Morgan M, et al. Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia. J Clin Oncol. 2011;29:2889\u201396.","journal-title":"J Clin Oncol"},{"key":"1287_CR6","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/leu.2011.382","volume":"26","author":"A Renneville","year":"2012","unstructured":"Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, Gardin C, et al. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia. 2012;26:1247\u201354.","journal-title":"Leukemia"},{"key":"1287_CR7","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1200\/JCO.2011.39.2092","volume":"30","author":"G Marcucci","year":"2012","unstructured":"Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mr\u00f3zek K, et al. Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia. J Clin Oncol. 2012;30:742\u201350.","journal-title":"J Clin Oncol"},{"key":"1287_CR8","doi-asserted-by":"publisher","first-page":"5824","DOI":"10.1182\/blood-2011-07-367961","volume":"119","author":"AFT Ribeiro","year":"2012","unstructured":"Ribeiro AFT, Pratcorona M, Erpelinck-Verschueren C, Rockova V, Sanders M, Abbas S, et al. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood. 2012;119:5824\u201331.","journal-title":"Blood"},{"key":"1287_CR9","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1182\/blood.2019003339","volume":"135","author":"MF Bezerra","year":"2020","unstructured":"Bezerra MF, Lima AS, Piqu\u00e9-Borr\u00e0s MR, Silveira DR, Coelho-Silva JL, Pereira-Martins DA, et al. Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis. Blood. 2020;135:870\u20135.","journal-title":"Blood"},{"key":"1287_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13045-014-0074-4","volume":"7","author":"S Loghavi","year":"2014","unstructured":"Loghavi S, Zuo Z, Ravandi F, Kantarjian HM, Bueso-Ramos C, Zhang L, et al. Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol OncolJ Hematol Oncol. 2014;7:74.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"1287_CR11","doi-asserted-by":"publisher","first-page":"e960","DOI":"10.1016\/j.clml.2021.07.011","volume":"21","author":"HAEA Elrhman","year":"2021","unstructured":"Elrhman HAEA, El-Meligui YM, Elalawi SM. Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients. Clin Lymphoma Myeloma Leuk. 2021;21:e960\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1287_CR12","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"1287_CR13","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/cas.15720","volume":"114","author":"S Wakita","year":"2023","unstructured":"Wakita S, Marumo A, Morita K, Kako S, Toya T, Najima Y, et al. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia. Cancer Sci. 2023;114:1297\u2013308.","journal-title":"Cancer Sci"},{"key":"1287_CR14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/leu.2012.168","volume":"27","author":"F Ostronoff","year":"2013","unstructured":"Ostronoff F, Othus M, Ho PA, Kutny M, Geraghty DE, Petersdorf SH, et al. Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report. Leukemia. 2013;27:238\u201341.","journal-title":"Leukemia"},{"key":"1287_CR15","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"1287_CR16","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"1287_CR17","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/ajh.26892","volume":"98","author":"M Lo","year":"2023","unstructured":"Lo M, Tsai XC, Lin C, Tien F, Kuo Y, Lee W, et al. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia. Am J Hematol. 2023;98:760\u20139.","journal-title":"Am J Hematol"},{"key":"1287_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0074-7","volume":"8","author":"HA Hou","year":"2018","unstructured":"Hou HA, Tsai CH, Lin CC, Chou WC, Kuo YY, Liu CY, et al. Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome. Blood Cancer J. 2018;8:39.","journal-title":"Blood Cancer J"},{"key":"1287_CR19","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","volume":"92","author":"D Grimwade","year":"1998","unstructured":"Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial. Blood. 1998;92:2322\u201333.","journal-title":"Blood"},{"key":"1287_CR20","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1002\/ajh.26734","volume":"97","author":"W Lee","year":"2022","unstructured":"Lee W, Lin C, Tsai C, Tseng M, Kuo Y, Liu M, et al. Effect of mutation allele frequency on the risk stratification of myelodysplastic syndrome patients. Am J Hematol. 2022;97:1589\u201398.","journal-title":"Am J Hematol"},{"key":"1287_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00975-8","volume":"14","author":"FM Tien","year":"2024","unstructured":"Tien FM, Yao CY, Tsai XCH, Lo MY, Chen CY, Lee WH, et al. Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations. Blood Cancer J. 2024;14:15.","journal-title":"Blood Cancer J"},{"key":"1287_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"1287_CR23","doi-asserted-by":"publisher","first-page":"D766","DOI":"10.1093\/nar\/gky955","volume":"47","author":"A Frankish","year":"2019","unstructured":"Frankish A, Diekhans M, Ferreira AM, Johnson R, Jungreis I, Loveland J, et al. GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res. 2019;47:D766\u201373.","journal-title":"Nucleic Acids Res"},{"key":"1287_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139\u201340.","journal-title":"Bioinformatics"},{"key":"1287_CR25","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci"},{"key":"1287_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0123-2","volume":"8","author":"FM Tien","year":"2018","unstructured":"Tien FM, Hou HA, Tsai CH, Tang JL, Chiu YC, Chen CY, et al. GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia. Blood Cancer J. 2018;8:87.","journal-title":"Blood Cancer J"},{"key":"1287_CR27","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562:526\u201331.","journal-title":"Nature"},{"key":"1287_CR28","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"The Cancer Genome Atlas Research Network.","year":"2013","unstructured":"The Cancer Genome Atlas Research Network. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. N Engl J Med. 2013;368:2059\u201374.","journal-title":"N Engl J Med"},{"key":"1287_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32103-8","volume":"13","author":"Y Tazi","year":"2022","unstructured":"Tazi Y, Arango-Ossa JE, Zhou Y, Bernard E, Thomas I, Gilkes A, et al. Unified classification and risk-stratification in Acute Myeloid Leukemia. Nat Commun. 2022;13:4622.","journal-title":"Nat Commun"},{"key":"1287_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/leu.2013.236","volume":"28","author":"HA Hou","year":"2014","unstructured":"Hou HA, Lin CC, Chou WC, Liu CY, Chen CY, Tang JL, et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia. 2014;28:50\u20138.","journal-title":"Leukemia"},{"key":"1287_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/sim.4780030106","volume":"3","author":"R Simon","year":"1984","unstructured":"Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med. 1984;3:35\u201344.","journal-title":"Stat Med"},{"key":"1287_CR32","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.1182\/blood-2023-182746","volume":"142","author":"J Wu","year":"2023","unstructured":"Wu J, Liu X, Li X, Wang Q, Zhang N, Zhou F. Mesenchymal Stromal Cell-Derived MMP14 Facilitates Leukemia Progression and Chemotherapy Resistance. Blood. 2023;142:5993.","journal-title":"Blood"},{"key":"1287_CR33","doi-asserted-by":"publisher","first-page":"5402","DOI":"10.1182\/bloodadvances.2020001802","volume":"4","author":"JM Ho","year":"2020","unstructured":"Ho JM, Dobson SM, Voisin V, McLeod J, Kennedy JA, Mitchell A, et al. CD200 expression marks leukemia stem cells in human AML. Blood Adv. 2020;4:5402\u201313.","journal-title":"Blood Adv"},{"key":"1287_CR34","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cell.2018.08.065","volume":"175","author":"F Coscia","year":"2018","unstructured":"Coscia F, Lengyel E, Duraiswamy J, Ashcroft B, Bassani-Sternberg M, Wierer M, et al. Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer. Cell. 2018;175:159\u2013170.e16.","journal-title":"Cell"},{"key":"1287_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5045\/br.2020.55.1.17","volume":"55","author":"DJ Park","year":"2020","unstructured":"Park DJ, Kwon A, Cho BS, Kim HJ, Hwang KA, Kim M, et al. Characteristics of DNMT3A mutations in acute myeloid leukemia. BLOOD Res. 2020;55:17\u201326.","journal-title":"BLOOD Res"},{"key":"1287_CR36","doi-asserted-by":"crossref","unstructured":"Delhommeau F, Valle VD, Mass\u00e9 A, Couedic JPL, L\u00e9cluse Y, Marzac C, et al. Mutation in TET2 in Myeloid Cancers. N Engl J Med. 2009;360:2289\u2013301.","DOI":"10.1056\/NEJMoa0810069"},{"key":"1287_CR37","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1182\/blood-2011-02-339747","volume":"118","author":"WC Chou","year":"2011","unstructured":"Chou WC, Chou SC, Liu CY, Chen CY, Hou HA, Kuo YY, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood. 2011;118:3803\u201310.","journal-title":"Blood"},{"key":"1287_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10238-024-01297-0","volume":"24","author":"X Pan","year":"2024","unstructured":"Pan X, Chang Y, Ruan G, Zhou S, Jiang H, Jiang Q, et al. TET2 mutations contribute to adverse prognosis in acute myeloid leukemia (AML): results from a comprehensive analysis of 502 AML cases and the Beat AML public database. Clin Exp Med. 2024;24:35.","journal-title":"Clin Exp Med"},{"key":"1287_CR39","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1200\/JCO.2010.32.7742","volume":"29","author":"KH Metzeler","year":"2011","unstructured":"Metzeler KH, Maharry K, Radmacher MD, Mr\u00f3zek K, Margeson D, Becker H, et al. TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol. 2011;29:1373\u201381.","journal-title":"J Clin Oncol"},{"key":"1287_CR40","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ng.3610","volume":"48","author":"X Zhang","year":"2016","unstructured":"Zhang X, Su J, Jeong M, Ko M, Huang Y, Park HJ, et al. DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells. Nat Genet. 2016;48:1014\u201323.","journal-title":"Nat Genet"},{"key":"1287_CR41","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/leu.2011.71","volume":"25","author":"R Itzykson","year":"2011","unstructured":"Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25:1147\u201352.","journal-title":"Leukemia"},{"key":"1287_CR42","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/leu.2011.342","volume":"26","author":"KH Metzeler","year":"2012","unstructured":"Metzeler KH, Walker A, Geyer S, Garzon R, Klisovic RB, Bloomfield CD, et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia. 2012;26:1106\u20137.","journal-title":"Leukemia"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01287-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01287-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01287-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:05:03Z","timestamp":1747699503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01287-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1287"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01287-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"13 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}